Page last updated: 2024-11-12
kelampayoside a
Description
kelampayoside A: a phenolic apioglucoside from the bark of Anthocephalus chinensis; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Anthocephalus | genus | [no description available] | Rubiaceae | The Madder plant family of the order Gentianales (formerly Rubiales), subclass Asteridae, class Magnoliopsida includes important medicinal plants that provide QUININE; IPECAC; and COFFEE. They have opposite leaves and interpetiolar stipules.[MeSH] |
Cross-References
Synonyms (11)
| Synonym |
|---|
| kelampayoside a |
| chebi:68963 , |
| CHEMBL1923077 |
| 87562-76-3 |
| 3,4,5-trimethoxyphenyl-1-o-beta-d-apiofuranosyl-(1->6)-o-beta-d-glucopyranoside |
| Q27137315 |
| FS-9123 |
| (2r,3s,4s,5r,6s)-2-[[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxymethyl]-6-(3,4,5-trimethoxyphenoxy)oxane-3,4,5-triol |
| 3,4,5-trimethoxyphenyl 6-o-d-apio--d-furanosyl--d-glucopyranoside |
| DTXSID101317142 |
| AKOS040761948 |
Roles (1)
| Role | Description |
|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
| Class | Description |
|---|
| glycoside | A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1442887 | Antiproliferative activity against human MCF7 cells by SRB assay | 2017 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8
| Bioactive drimane sesquiterpenoids and aromatic glycosides from Cinnamosma fragrans. |
| AID632953 | Cytotoxicity against human CCD-18Co cells after 72 hrs by MTS assay | 2011 | Journal of natural products, Nov-28, Volume: 74, Issue:11
| Phenolic glycosides from sugar maple (Acer saccharum) bark. |
| AID1761969 | Analgesic activity against paclitaxel-induced cold allodynia in C57BL/6 mouse model at 10 mg/kg, po administered at day 14 and day 25 of post paclitaxel stimulation and measured after 1 hr | 2021 | Journal of natural products, 03-26, Volume: 84, Issue:3
| Aromatic and Aliphatic Apiuronides from the Bark of |
| AID632952 | Cytotoxicity against human Caco2 cells after 72 hrs by MTS assay | 2011 | Journal of natural products, Nov-28, Volume: 74, Issue:11
| Phenolic glycosides from sugar maple (Acer saccharum) bark. |
| AID632951 | Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay | 2011 | Journal of natural products, Nov-28, Volume: 74, Issue:11
| Phenolic glycosides from sugar maple (Acer saccharum) bark. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |